Irresponsive risk with anti-tuberculosis therapy in TB&HIV patients with active hepatitis B virus were 3.34 times as much as those with latent viral hepatitis B and the difference was statistically significant (P=0.0181; RR=3.34; 95% CI: 1.34 - 3.79).